Deciphering the potential ability of DExD/H-box helicase 60 (DDX60) on the proliferation, diagnostic and prognostic biomarker in pancreatic cancer: a research based on silico, RNA-seq and molecular biology experiment.

IF 2.7 3区 生物学
Dongdong Zhang, Enze Zhang, Ying Cai, Yixin Sun, Peiji Zeng, Xiaohua Jiang, Yifan Lian
{"title":"Deciphering the potential ability of DExD/H-box helicase 60 (DDX60) on the proliferation, diagnostic and prognostic biomarker in pancreatic cancer: a research based on silico, RNA-seq and molecular biology experiment.","authors":"Dongdong Zhang, Enze Zhang, Ying Cai, Yixin Sun, Peiji Zeng, Xiaohua Jiang, Yifan Lian","doi":"10.1186/s41065-024-00361-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Pancreatic cancer is one of the most malignant abdominal tumors. DDX60 has been shown to be associated with a variety of tumor biological processes. However, DDX60 in pancreatic cancer has not been reported. Our study confirmed that DDX60 can serve as a novel biomarker for diagnosis and treatment of pancreatic cancer.</p><p><strong>Materials and methods: </strong>We downloaded pancreatic cancer datasets from GEO and TCGA databases, respectively. To investigate the relationship between DDX60 expression and prognosis in pancreatic cancer. GSEA analysis was performed on DDX60. We performed RNA-seq to further explore the downstream biological targets of DDX60 and the signaling pathways that may be involved in pancreatic cancer. Finally, we tested it through molecular biology experiments. First, we constructed the plasmid and tested the plasmid effect by WB. Then MTT assay was performed to explore the effect of DDX60 knockout on the proliferation of pancreatic cancer cells. LDH assay was performed to explore the effect of DDX60 on the release of lactate dehydrogenase from tumor cells. The effect of DDX60 on cell proliferation was further explored by clonal formation experiment. Continue to explore clinical therapeutic drugs sensitive to DDX60 targets.</p><p><strong>Results: </strong>By analyzing the GSE71729, GSE183795, GSE16515, GSE28735 and GSE62452 data sets, we found that DDX60 was highly expressed in pancreatic cancer. And is associated with poorer outcomes for pancreatic patients. The mRNA expression level of DDX60 was correlated with lymph node metastasis and grade in clinical pancreatic patients. Through the results of RNA-seq analysis, GO and KEGG analysis showed that DDX60 may be associated with cell cycle in pancreatic cancer. Through molecular biology experiments (MTT, LDH, and clonal formation experiment), we found that When DDX60 is knocked down in pancreatic cancer cells, the proliferation ability of tumor cells is significantly decreased. Several drugs targeting about DDX60 have been found, such as JW-7-52-1, this could provide direction for drug therapy against the DDX60 target.</p><p><strong>Conclusion: </strong>In summary, DDX60 can be used as a novel biomarker related to the diagnosis and treatment of pancreatic cancer, participate in tumor proliferation, and is associated with poor prognosis in patients.</p>","PeriodicalId":12862,"journal":{"name":"Hereditas","volume":"162 1","pages":"6"},"PeriodicalIF":2.7000,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11753068/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hereditas","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1186/s41065-024-00361-9","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Pancreatic cancer is one of the most malignant abdominal tumors. DDX60 has been shown to be associated with a variety of tumor biological processes. However, DDX60 in pancreatic cancer has not been reported. Our study confirmed that DDX60 can serve as a novel biomarker for diagnosis and treatment of pancreatic cancer.

Materials and methods: We downloaded pancreatic cancer datasets from GEO and TCGA databases, respectively. To investigate the relationship between DDX60 expression and prognosis in pancreatic cancer. GSEA analysis was performed on DDX60. We performed RNA-seq to further explore the downstream biological targets of DDX60 and the signaling pathways that may be involved in pancreatic cancer. Finally, we tested it through molecular biology experiments. First, we constructed the plasmid and tested the plasmid effect by WB. Then MTT assay was performed to explore the effect of DDX60 knockout on the proliferation of pancreatic cancer cells. LDH assay was performed to explore the effect of DDX60 on the release of lactate dehydrogenase from tumor cells. The effect of DDX60 on cell proliferation was further explored by clonal formation experiment. Continue to explore clinical therapeutic drugs sensitive to DDX60 targets.

Results: By analyzing the GSE71729, GSE183795, GSE16515, GSE28735 and GSE62452 data sets, we found that DDX60 was highly expressed in pancreatic cancer. And is associated with poorer outcomes for pancreatic patients. The mRNA expression level of DDX60 was correlated with lymph node metastasis and grade in clinical pancreatic patients. Through the results of RNA-seq analysis, GO and KEGG analysis showed that DDX60 may be associated with cell cycle in pancreatic cancer. Through molecular biology experiments (MTT, LDH, and clonal formation experiment), we found that When DDX60 is knocked down in pancreatic cancer cells, the proliferation ability of tumor cells is significantly decreased. Several drugs targeting about DDX60 have been found, such as JW-7-52-1, this could provide direction for drug therapy against the DDX60 target.

Conclusion: In summary, DDX60 can be used as a novel biomarker related to the diagnosis and treatment of pancreatic cancer, participate in tumor proliferation, and is associated with poor prognosis in patients.

DExD/H-box解旋酶60 (DDX60)对胰腺癌增殖、诊断和预后生物标志物的潜在作用:基于硅基、RNA-seq和分子生物学实验的研究
背景:胰腺癌是最恶性的腹部肿瘤之一。DDX60已被证明与多种肿瘤生物学过程有关。然而,DDX60在胰腺癌中的表达尚未见报道。我们的研究证实了DDX60可以作为胰腺癌诊断和治疗的一种新的生物标志物。材料和方法:我们分别从GEO和TCGA数据库下载胰腺癌数据集。目的探讨胰腺癌DDX60表达与预后的关系。DDX60进行GSEA分析。我们通过RNA-seq进一步探索DDX60的下游生物学靶点以及可能参与胰腺癌的信号通路。最后,我们通过分子生物学实验进行验证。首先构建质粒,并用WB检测质粒效应。MTT法探讨敲除DDX60对胰腺癌细胞增殖的影响。采用LDH法探讨DDX60对肿瘤细胞乳酸脱氢酶释放的影响。通过克隆形成实验进一步探讨DDX60对细胞增殖的影响。继续探索对DDX60靶点敏感的临床治疗药物。结果:通过分析GSE71729、GSE183795、GSE16515、GSE28735和GSE62452数据集,我们发现DDX60在胰腺癌中呈高表达。胰腺癌患者的预后较差。DDX60 mRNA表达水平与临床胰腺患者淋巴结转移及分级相关。通过RNA-seq分析、GO和KEGG分析结果显示,DDX60可能与胰腺癌细胞周期有关。通过分子生物学实验(MTT、LDH、克隆形成实验),我们发现当DDX60在胰腺癌细胞中被敲低时,肿瘤细胞的增殖能力明显下降。目前已经发现了几种靶向DDX60的药物,如JW-7-52-1,这为针对DDX60靶点的药物治疗提供了方向。结论:综上所述,DDX60可作为与胰腺癌诊断和治疗相关的新型生物标志物,参与肿瘤增殖,与患者预后不良相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Hereditas
Hereditas Biochemistry, Genetics and Molecular Biology-Genetics
CiteScore
3.80
自引率
3.70%
发文量
0
期刊介绍: For almost a century, Hereditas has published original cutting-edge research and reviews. As the Official journal of the Mendelian Society of Lund, the journal welcomes research from across all areas of genetics and genomics. Topics of interest include human and medical genetics, animal and plant genetics, microbial genetics, agriculture and bioinformatics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信